Long-Term Side Effects of GLP-1: What Research Shows | telos rx
Fresh avocado, eggs, mushrooms and greens on a cutting board, a nutrient-dense meal for people on long-term GLP-1 therapy
← Back to blog
gallbladder risk

Long-Term Side Effects of GLP-1: What the Research Shows

By TelosRX Editorial Team

The long-term side effects of GLP-1 medications studied so far include gallbladder problems, lean muscle loss and rare pancreatitis. Thyroid and eye risks remain open questions. TelosRX reviews what multi-year trials actually found, study by study.

Most people know the first-month story. Nausea, a full stomach, maybe some constipation. The bigger question is what happens in year two, three or five.

Good news: we now have multi-year data. Less good news: some answers are still incomplete. Here's what the long-term side effects of GLP-1 drugs look like when you read the studies, not the headlines.

Long-Term GLP-1 Side Effects: The Evidence at a Glance

Start with the "type" column. A randomized trial and an insurance-claims study don't carry the same weight.

Concern Key study Type What it found Evidence strength
Overall safety over ~3 years SELECT, 2023 Randomized trial, 17,604 adults No new safety signals; more people stopped the drug for side effects Strong
GI effects over 2 years STEP 5, 2022 Randomized trial GI effects most common, mostly mild to moderate and temporary Strong
Gallbladder disease JAMA Internal Medicine meta-analysis, 2022 Review of 76 trials Higher risk, especially at higher doses and longer use Strong
Muscle and lean mass STEP 1 body-composition substudy, 2021 Randomized trial subgroup A meaningful share of weight lost was lean mass Moderate
Serious GI events JAMA research letter, 2023 Claims database study Higher risk of pancreatitis, bowel obstruction and gastroparesis; absolute risk low Moderate
Thyroid cancer Diabetes Care, 2023 Case-control study Possible association after 1 to 3 years; other studies disagree Low to moderate
Rare eye condition (NAION) JAMA Ophthalmology, 2024 Retrospective cohort Association reported; cause not proven Low to moderate

Finding 1: The Longest Trial Found No New Safety Signals

The SELECT trial, published in the New England Journal of Medicine in 2023, is the biggest long-term look we have. It followed 17,604 adults with overweight or obesity and heart disease. None had diabetes. Average follow-up ran more than three years.

Semaglutide 2.4 mg lowered the rate of major heart events compared with placebo. That result led to an FDA-approved heart-risk indication for Wegovy®.

On safety, the picture was steady. Serious adverse events were not higher on semaglutide. But more people stopped the drug because of side effects, about 16.6% versus 8.2% on placebo. GI symptoms drove most of those stops.

What it shows: years of use didn't reveal a hidden new danger. What it doesn't show: effects beyond about four years, or results in people without heart disease.

Finding 2: GI Side Effects Are Common, but Mostly Fade

The STEP 5 trial in Nature Medicine ran for two full years. It's one of the longest placebo-controlled trials of semaglutide for weight management.

GI effects were the most reported side effects. Most were mild to moderate. Most showed up during dose increases, then eased.

  • Nausea, diarrhea, constipation and vomiting led the list.
  • Symptoms clustered in the early months and after each dose step-up.
  • Few people had GI effects that lasted the whole two years.

A 2026 review in the Journal of Clinical Investigation found the same pattern across longer trials. Nausea was the leading reason people quit, followed by vomiting and diarrhea.

Finding 3: Gallbladder Risk Rises With Dose and Duration

This is the clearest long-term signal in the research. A 2022 meta-analysis in JAMA Internal Medicine pooled 76 randomized trials. GLP-1 drugs were associated with a higher risk of gallbladder and bile duct disease, including gallstones.

The risk looked higher in three situations:

  1. Higher doses, like those used for weight management.
  2. Longer treatment.
  3. Use for weight loss rather than diabetes alone.

Fast weight loss from any cause raises gallstone risk. So part of this may come from the weight loss itself. Our guide to GLP-1 gallbladder problems covers symptoms to watch for.

Finding 4: Some Weight Lost Is Lean Mass

The STEP 1 trial, published in the New England Journal of Medicine in 2021, scanned a subgroup with DXA (a body-composition X-ray). Fat mass fell more than lean mass. Still, lean mass made up a meaningful share of total weight lost, roughly two-fifths.

Lean mass includes muscle, but also water and organ tissue. So this isn't pure muscle loss. Researchers note that diet-only weight loss shows a similar split.

The concern is long-term. If weight comes back after stopping, it may return as more fat than muscle. That's why protein and strength training matter on any GLP-1 plan.

Curious how a GLP-1 plan might fit your goals? See how TelosRX approaches semaglutide through an asynchronous online evaluation. Any prescription is subject to medical approval by a licensed provider.

Finding 5: Rare but Serious GI Events

A 2023 research letter in JAMA compared GLP-1 users with people taking a different weight-loss drug, bupropion-naltrexone. It used a large insurance-claims database.

GLP-1 use for weight loss was associated with a higher risk of three conditions:

  • Pancreatitis: inflammation of the pancreas.
  • Bowel obstruction: a blockage in the intestines.
  • Gastroparesis: stomach paralysis, or very slow emptying.

The absolute risks stayed low. Claims data also can't prove cause. Large trials have not consistently confirmed a pancreatitis link, but labels still list it as a rare, serious risk. See our page on GLP-1 and pancreatitis risk.

One related label update matters if you need surgery. Slowed stomach emptying may raise aspiration risk under anesthesia. Always tell your care team you take a GLP-1.

Finding 6: The Thyroid Question Isn't Settled

Brand GLP-1 labels carry a boxed warning. In rodents, these drugs caused thyroid C-cell tumors. People with a personal or family history of medullary thyroid cancer or MEN 2 shouldn't use them.

Human data are mixed. A 2023 French case-control study in Diabetes Care linked 1 to 3 years of use with a higher risk of thyroid cancer. A 2024 Scandinavian cohort study in the BMJ did not find a substantially higher risk.

Increased thyroid screening in GLP-1 users may explain part of the signal. More cancers get found when more people get checked. For now, it's an open question, not a confirmed effect.

Finding 7: A Rare Optic Nerve Condition

NAION (nonarteritic anterior ischemic optic neuropathy) is a sudden loss of blood flow to the optic nerve. It can cause painless vision loss in one eye.

A 2024 study in JAMA Ophthalmology reviewed records at one Boston eye hospital. Patients prescribed semaglutide had a higher rate of NAION than those on other drugs. Later studies have been mixed.

In 2025, European regulators listed NAION as a very rare side effect of semaglutide. Sudden vision changes on any GLP-1 deserve urgent medical attention.

What We Still Don't Know

Honest science has gaps. Here's what long-term research hasn't answered yet:

  • Decade-plus effects: weight-management trials mostly run 2 to 4 years.
  • Bone density: sustained weight loss may reduce bone mass, but GLP-1-specific data are limited.
  • Newer drugs: tirzepatide's three-year SURMOUNT-1 extension showed no new safety signals, but its record is shorter.
  • Compounded versions: long-term trials used brand products only.

Brand Wegovy® and Zepbound® are FDA-approved for chronic weight management. Compounded semaglutide and tirzepatide are not FDA-approved. Learn about tirzepatide at TelosRX.

How to Lower Your Long-Term Risk

None of this replaces your provider's advice. But the research points to a few practical habits:

  1. Eat enough protein. It helps protect lean mass while you lose weight.
  2. Lift something. Two or more strength sessions a week support muscle.
  3. Increase doses slowly. Gradual titration (step-by-step dose increases) eases GI effects.
  4. Know the red flags. Severe belly pain, right-side pain after meals or sudden vision change need prompt care.
  5. Keep labs current. Regular check-ins let your provider spot trends early.

Thinking about how long to stay on treatment? Our guide to long-term GLP-1 maintenance covers what extended treatment looks like. With TelosRX, you can message your provider through your asynchronous portal whenever symptoms change.

Frequently Asked Questions

What are the long-term side effects of GLP-1 medications?

Studies lasting two to four years point to gallbladder problems, loss of some lean mass, and rare risks like pancreatitis and gastroparesis. Thyroid cancer and a rare optic nerve condition called NAION are still under study. GI effects are the most common but usually fade after dose increases.

Is it safe to take a GLP-1 long term?

The longest trial, SELECT, followed over 17,000 adults for more than three years and found no new safety signals. More people stopped the drug due to GI side effects, though. Long-term use appears reasonable for many people, with regular provider check-ins and attention to warning symptoms.

Does GLP-1 cause muscle loss?

Some weight lost on a GLP-1 is lean mass, which includes muscle, water and organ tissue. In the STEP 1 body-composition substudy, lean mass made up roughly two-fifths of weight lost. Eating enough protein and doing strength training are the main strategies researchers recommend.

Do GLP-1 side effects go away over time?

Most GI side effects, like nausea and diarrhea, show up early or after a dose increase and then ease. In the two-year STEP 5 trial, most were mild to moderate and temporary. Some risks, like gallbladder disease, relate more to dose, duration and weight loss itself.

Does semaglutide cause thyroid cancer?

It's not settled. Semaglutide caused thyroid C-cell tumors in rodents, so labels carry a boxed warning. A French study linked one to three years of use with higher thyroid cancer risk, but a large Scandinavian study did not. People with medullary thyroid cancer history should avoid GLP-1s.

What happens to your body after years on a GLP-1?

Multi-year trials show sustained weight loss for many people, with lower heart-event risk in SELECT. Side effects tend to settle after the first months. Ongoing considerations include gallbladder health, lean mass, nutrition and regular lab monitoring. Data beyond about four years remain limited.

Are long-term side effects of tirzepatide different from semaglutide?

They look broadly similar so far, since both act on GLP-1 receptors. Tirzepatide's three-year SURMOUNT-1 extension reported no new safety signals, with GI effects most common. Tirzepatide has a shorter track record, so long-term data are thinner than for semaglutide.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX